Streetbeat News

Products Services

AAPL

Apple Inc. has introduced a new 'Journal' app with the latest iOS 17.2 update, which allows users to create digital diaries using photos, videos, and audio. The app features machine learning, tailored prompts, and robust security with end-to-end encryption. Apple's stock saw a 1.4% decline on Monday, trading 2.7 percentage points below its all-time high.

Portfolio Pulse from Piero Cingari

December 11, 2023 | 9:42 pm

ADAUSD

BTCUSD

ETHUSD

Cardano (ADA) experienced a significant 8% decline, outpacing Bitcoin (BTC) and Ethereum (ETH) which both fell over 6%. ADA's open interest dropped by 14%, indicating a market outflow. Analyst Ali Martinez signaled a potential short-term correction for ADA. The Cardano community celebrated Ada Lovelace's 208th birthday, and the Cardano Foundation launched a self-sovereign Identity Wallet. Charles Hoskinson's post about his dog Freya inadvertently caused a rally in the Freya NFT project, which he later clarified he was not endorsing.

Portfolio Pulse from Khyathi Dalal

December 11, 2023 | 9:42 pm

ORCL

Oracle Corporation (NYSE:ORCL) reported Q2 earnings of $1.34 per share, beating estimates by $0.02, but missed revenue expectations with $12.94 billion against the forecasted $13.05 billion. Despite the revenue shortfall, Oracle highlighted a 25% increase in cloud revenue, with cloud infrastructure up 52% and cloud application revenue up 15%. The company's operating cash flow over the last twelve months was $17 billion, and free cash flow was $10.1 billion. CEO Safra Catz emphasized the growing demand for Cloud Infrastructure and Generative AI services, with Remaining Performance Obligations over $65 billion. After the report, ORCL shares dropped 8.91% in after-hours trading to $104.83.

Portfolio Pulse from Ryan Gustafson

December 11, 2023 | 9:40 pm

INAB

IN8bio's stock price has risen following the announcement of positive updated data from its Phase 1 trial of INB-100 for hematologic malignancies.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 9:35 pm

PFE

Pfizer has announced that the FDA has accepted its Biologics License Application for Marstacimab. Additionally, the European Marketing Authorization Application for Marstacimab has passed validation and is currently under review by the European Medicines Agency (EMA).

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 9:31 pm

MGRX

Mangoceuticals has entered into a marketing agreement with Marius Pharmaceuticals, according to a Dec. 10 SEC 8K filing. The agreement grants Mangoceuticals the rights to use the trademark 'Kyzatrex' for oral testosterone undecanoate softgel capsules and allows them to sell Kyzatrex on their website.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 9:30 pm

F

Ford Motor Co. is reportedly planning to cut production of its F-150 Lightning electric vehicle by half in 2024, according to a memo sent to suppliers. This decision could signal a shift in Ford's strategy or a response to market demand and supply chain issues.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 9:26 pm

EBAY

Topps, owned by Fanatics, is releasing a 2023 Bowman Draft baseball box featuring rare and autographed cards of NFL legend Tom Brady in a Montreal Expos jersey. Fanatics CEO Michael Rubin announced the inclusion of Brady's 'first-ever official' baseball cards. An anonymous collector has offered a $500,000 bounty for a specific gold autograph card. The release has sparked significant interest in the sports card market, with non-auto cards already appearing on eBay. Odds of pulling a Brady card vary, with autographed versions being particularly rare.

Portfolio Pulse from Chris Katje

December 11, 2023 | 9:24 pm

AMRC

Ameresco, Inc. has been awarded contracts to develop two clean energy facilities by Hawaiian Electric Company. This move aligns with the increasing demand for renewable energy solutions and may positively impact Ameresco's revenue and growth prospects in the renewable energy sector.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 9:23 pm

ACHV

Achieve Life Sciences announced a potential delay in the NDA filing for its drug candidate, Cytisinicline, due to the FDA's request for additional long-term safety data. The FDA supports an NDA submission based on current Phase 3 trials but requires safety data beyond 12 weeks to assess risks for a drug intended for chronic, intermittent use.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 9:17 pm